Note 2 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2020

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Three Months Ended September 30, 2020
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	1,137,000	$	32,000	$	--	$	1,169,000
BioArchive		337,000		282,000		--		619,000
CAR-TXpress		332,000		22,000		71,000		425,000
Manual Disposables		100,000		--		--		100,000
Other		26,000		--		16,000		42,000
Total	$	1,932,000	$	336,000	$	87,000	$	2,355,000

	Nine Months Ended September 30, 2020
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	4,009,000	$	103,000	$	--	$	4,112,000
BioArchive		675,000		900,000		--		1,575,000
CAR-TXpress		1,035,000		47,000		214,000		1,296,000
Manual Disposables		499,000		--		--		499,000
Other		276,000		--		39,000		315,000
Total	$	6,494,000	$	1,050,000	$	253,000	$	7,797,000

	Three Months Ended September 30, 2019
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	2,255,000	$	51,000	$	--	$	2,306,000
BioArchive		243,000		351,000		--		594,000
Manual Disposables		221,000		--		--		221,000
CAR-TXpress		875,000		10,000		33,000		918,000
Other		--		--		19,000		19,000
Total	$	3,594,000	$	412,000	$	52,000	$	4,058,000

	Nine Months Ended September 30, 2019
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
AXP	$	6,550,000	$	160,000	$	--	$	6,710,000
BioArchive		1,274,000		1,117,000		--		2,391,000
Manual Disposables		764,000		--		--		764,000
CAR-TXpress		1,365,000		6,000		33,000		1,404,000
Other		5,000		11,000		40,000		56,000
Total	$	9,958,000	$	1,294,000	$	73,000	$	11,325,000

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]

	Remainder of 2020		2021		2022		2023		2024 and beyond		Total
Service revenue	$	310,000	$	958,000	$	561,000	$	298,000	$	38,000	$	2,165,000
Clinical revenue		3,000		13,000		13,000		13,000		175,000		217,000
Exclusivity fee		71,000		286,000		286,000		286,000		761,000		1,690,000
Total	$	384,000	$	1,257,000	$	860,000	$	597,000	$	974,000	$	4,072,000

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	2020		2019
Common stock equivalents of convertible promissory note and accrued interest		6,988,334		6,013,667
Vested Series A warrants		40,441		40,441
Unvested Series A warrants (1)		69,853		69,853
Warrants – other		1,006,190		1,300,091
Stock options		892,149		296,029
Total		8,996,967		7,720,081